Highlights of EMA management board October meeting

3 October 2025

Following its October management board meeting, the European Medicines Agency (EMA) has presented results and achievements of its operations for the first half of 2025.

It noted that, between January and June, applications for new medicines (orphan and non-orphan) remain at the same high level as last year (29 versus 30 applications in Q1-Q2 2024). In veterinary medicines, the board noted the same high level of applications as in 2024 (12 versus 11 applications in Q1-Q2 2024) and anticipates an increase above the initial forecast for the whole of 2025.

The board welcomed the positive trend in reduction of company clock steps in Q1-Q2 2025 - an average of 150 days compared to an average of 182 days in 2024 (an approximately 18% reduction).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK